BTC Capital Management Inc. Purchases 1,265 Shares of Eli Lilly and Company (NYSE:LLY)

BTC Capital Management Inc. increased its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 13.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,502 shares of the company's stock after purchasing an additional 1,265 shares during the period. BTC Capital Management Inc.'s holdings in Eli Lilly and Company were worth $8,675,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Mascagni Wealth Management Inc. acquired a new position in shares of Eli Lilly and Company in the 4th quarter worth $43,000. FPC Investment Advisory Inc. boosted its position in shares of Eli Lilly and Company by 358.3% in the 4th quarter. FPC Investment Advisory Inc. now owns 55 shares of the company's stock valued at $45,000 after purchasing an additional 43 shares during the period. Prudent Man Investment Management Inc. purchased a new position in Eli Lilly and Company in the 4th quarter worth about $48,000. Compass Financial Services Inc purchased a new position in Eli Lilly and Company in the 4th quarter worth about $50,000. Finally, Fiduciary Advisors Inc. acquired a new stake in Eli Lilly and Company during the 4th quarter worth about $58,000. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Stock Up 2.2%

Shares of NYSE LLY traded up $15.76 during trading hours on Friday, hitting $738.33. The stock had a trading volume of 6,102,436 shares, compared to its average volume of 3,639,718. The firm's 50-day moving average price is $776.85 and its two-hundred day moving average price is $799.88. Eli Lilly and Company has a 52 week low of $677.09 and a 52 week high of $972.53. The company has a market capitalization of $699.74 billion, a P/E ratio of 63.05, a P/E/G ratio of 1.40 and a beta of 0.48. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The business had revenue of $12.73 billion during the quarter, compared to the consensus estimate of $12.77 billion. During the same period in the prior year, the firm earned $2.58 earnings per share. The business's revenue was up 45.2% on a year-over-year basis. Analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be issued a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a yield of 0.81%. The ex-dividend date is Friday, May 16th. Eli Lilly and Company's dividend payout ratio is presently 48.82%.

Insider Buying and Selling at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the company's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the sale, the chief accounting officer now owns 5,840 shares in the company, valued at approximately $4,778,521.60. This represents a 14.62% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.13% of the company's stock.

Analysts Set New Price Targets

Several research analysts have commented on LLY shares. Hsbc Global Res cut shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a report on Monday, April 28th. Truist Financial lifted their price objective on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a "buy" rating in a research report on Monday, February 3rd. HSBC downgraded shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and cut their target price for the company from $1,150.00 to $700.00 in a research note on Monday, April 28th. The Goldman Sachs Group upgraded Eli Lilly and Company from a "neutral" rating to a "buy" rating and lowered their price target for the company from $892.00 to $888.00 in a report on Tuesday, April 8th. Finally, Wall Street Zen upgraded Eli Lilly and Company from a "hold" rating to a "buy" rating in a research report on Friday. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eighteen have issued a buy rating to the stock. Based on data from MarketBeat, Eli Lilly and Company presently has an average rating of "Moderate Buy" and a consensus target price of $1,011.37.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.